Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country entities : Hoth therapeutics, inc. save search
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 5.37%
H: 0.64%
C: -12.1%
obesity treatment wholly
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: -2.31%
H: 4.72%
C: -3.15%
patent therapeutics
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery
Published: 2023-10-05 (Crawled : 14:30) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 2.9%
H: 16.2%
C: -2.11%
drug initiative therapeutics
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Published: 2023-09-13 (Crawled : 20:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 16.04%
H: 8.36%
C: -38.26%
nasdaq direct offering therapeutics
Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 4.61%
H: 2.2%
C: 0.88%
positive trial therapeutics results
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease
Published: 2023-08-09 (Crawled : 17:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 8.89%
H: 2.04%
C: 2.04%
disease positive treatment preclinical alzheimer's therapeutics ht-alz results
Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial
Published: 2023-07-25 (Crawled : 13:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 1.15%
H: 2.27%
C: 1.89%
trial therapeutics milestone
Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease
Published: 2023-06-06 (Crawled : 15:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 88.3%
H: 21.47%
C: -5.37%
disease positive treatment preclinical alzheimer's therapeutics ht-alz results
Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-03-08 (Crawled : 17:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: -0.37%
H: 4.49%
C: 2.62%
active collaboration trial therapeutics therapy cancer growth
Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001
Published: 2022-12-01 (Crawled : 18:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 0.49%
H: 9.58%
C: -1.72%
ht-001 drug application therapeutics submission
Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers
Published: 2021-04-20 (Crawled : 14:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 23.29%
H: 7.22%
C: -14.44%
cancer growth
Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial
Published: 2021-04-12 (Crawled : 15:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 2.25%
H: 1.65%
C: -8.79%
cancer trial
Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006
Published: 2021-03-17 (Crawled : 18:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 1.42%
H: 7.44%
C: 1.4%
iot
Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment
Published: 2021-02-24 (Crawled : 18:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: -1.94%
H: 42.03%
C: 10.24%
alzheimer treatment therapeutics alzheimer’s alzheimer's
Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)
Published: 2021-02-18 (Crawled : 19:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 0.99%
H: 14.01%
C: -13.03%
disease treatment drug
Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth Invitational 2021 Virtual Conference
Published: 2021-02-17 (Crawled : 15:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: -0.4%
H: 25.4%
C: 22.58%
growth research
Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules
Published: 2021-01-05 (Crawled : 16:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: -13.98%
H: 16.26%
C: 6.53%
nasdaq
Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients
Published: 2020-12-23 (Crawled : 16:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: -0.6%
H: 13.94%
C: 0.0%
drug cancer treatment new drug
Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model
Published: 2020-12-21 (Crawled : 15:00) - biospace.com/
HOTH | $1.19 1.2% 17K
|
Health Technology
|
| O: 2.41%
H: 0.0%
C: -1.76%
drug endocannabinoid lupus
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.